Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma - A Southwest Oncology Group study

M. Ernest Marshall; Michael K. Wolf; E. David Crawford; Sarah Taylor; Brent Blumenstein; Robert Flanigan; Fredrick J. Meyers; Harry E. Hynes; Bart Barlogie; Mario Eisenberger

doi:10.1007/BF00874157

Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma - A Southwest Oncology Group study

M. Ernest Marshall, Michael K. Wolf, E. David Crawford, Sarah Taylor, Brent Blumenstein, Robert Flanigan, Fredrick J. Meyers, Harry E. Hynes, Bart Barlogie, Mario Eisenberger

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Forty-nine patients with metastatic or recurrent renal cell carcinoma were treated on a phase II trial of Echinomycin. Treatment consisted of Echinomycin 1.25 mg/m² intravenously every 28 days. Among the 47 evaluable patients there were no complete responses and only one partial response for an overall response rate of 2% (95% confidence interval, 0-11%). Eighteen patients (38%) experienced toxicity of grade 3 or worse. The most common toxicities were nausea and vomiting. The results of this study indicate that Echinomycin is not sufficiently active to warrant further trials for the treatment of renal cell carcinoma.

Original language	English
Pages (from-to)	207-209
Number of pages	3
Journal	Investigational New Drugs
Volume	11
Issue number	2-3
DOIs	https://doi.org/10.1007/BF00874157
State	Published - Jun 1993
Externally published	Yes

Keywords

echinomycin
kidney
renal cell carcinoma

Access to Document

10.1007/BF00874157

Cite this

@article{81099155610c49fe8ca92dcbab183b75,

title = "Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma - A Southwest Oncology Group study",

abstract = "Forty-nine patients with metastatic or recurrent renal cell carcinoma were treated on a phase II trial of Echinomycin. Treatment consisted of Echinomycin 1.25 mg/m2 intravenously every 28 days. Among the 47 evaluable patients there were no complete responses and only one partial response for an overall response rate of 2% (95% confidence interval, 0-11%). Eighteen patients (38%) experienced toxicity of grade 3 or worse. The most common toxicities were nausea and vomiting. The results of this study indicate that Echinomycin is not sufficiently active to warrant further trials for the treatment of renal cell carcinoma.",

keywords = "echinomycin, kidney, renal cell carcinoma",

author = "Marshall, {M. Ernest} and Wolf, {Michael K.} and Crawford, {E. David} and Sarah Taylor and Brent Blumenstein and Robert Flanigan and Meyers, {Fredrick J.} and Hynes, {Harry E.} and Bart Barlogie and Mario Eisenberger",

year = "1993",

month = jun,

doi = "10.1007/BF00874157",

language = "English",

volume = "11",

pages = "207--209",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

number = "2-3",

}

TY - JOUR

T1 - Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma - A Southwest Oncology Group study

AU - Marshall, M. Ernest

AU - Wolf, Michael K.

AU - Crawford, E. David

AU - Taylor, Sarah

AU - Blumenstein, Brent

AU - Flanigan, Robert

AU - Meyers, Fredrick J.

AU - Hynes, Harry E.

AU - Barlogie, Bart

AU - Eisenberger, Mario

PY - 1993/6

Y1 - 1993/6

N2 - Forty-nine patients with metastatic or recurrent renal cell carcinoma were treated on a phase II trial of Echinomycin. Treatment consisted of Echinomycin 1.25 mg/m2 intravenously every 28 days. Among the 47 evaluable patients there were no complete responses and only one partial response for an overall response rate of 2% (95% confidence interval, 0-11%). Eighteen patients (38%) experienced toxicity of grade 3 or worse. The most common toxicities were nausea and vomiting. The results of this study indicate that Echinomycin is not sufficiently active to warrant further trials for the treatment of renal cell carcinoma.

AB - Forty-nine patients with metastatic or recurrent renal cell carcinoma were treated on a phase II trial of Echinomycin. Treatment consisted of Echinomycin 1.25 mg/m2 intravenously every 28 days. Among the 47 evaluable patients there were no complete responses and only one partial response for an overall response rate of 2% (95% confidence interval, 0-11%). Eighteen patients (38%) experienced toxicity of grade 3 or worse. The most common toxicities were nausea and vomiting. The results of this study indicate that Echinomycin is not sufficiently active to warrant further trials for the treatment of renal cell carcinoma.

KW - echinomycin

KW - kidney

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0027244912&partnerID=8YFLogxK

U2 - 10.1007/BF00874157

DO - 10.1007/BF00874157

M3 - Article

C2 - 8262733

AN - SCOPUS:0027244912

SN - 0167-6997

VL - 11

SP - 207

EP - 209

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 2-3

ER -

Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma - A Southwest Oncology Group study

Abstract

Keywords

Access to Document

Fingerprint

Cite this